Form 4: Akoya Biosciences Director Disposes of All Holdings Following Quanterix Merger

Akoya Biosciences Director Scott Mendel reported the disposition of all his common stock and stock options in Akoya Biosciences, Inc. on July 8, 2025, as a result of the company's merger with Quanterix Corporation.

Summary

• Scott Mendel, a Director of Akoya Biosciences, Inc., reported the disposition of his entire holdings in the company.
• On July 8, 2025, Akoya Biosciences, Inc. merged with Wellfleet Merger Sub, Inc., a wholly owned subsidiary of Quanterix Corporation, with Akoya Biosciences surviving as a wholly owned subsidiary of Quanterix.
• Mendel disposed of 28,500 shares of Akoya Biosciences common stock. Each share was converted into 0.1461 of a share of Quanterix common stock and $0.38 in cash.
• Mendel also disposed of 217,392 stock options. These options were accelerated, and those with an exercise price equal to or greater than the Per Share Merger Consideration were terminated and cancelled for no consideration.

Sentiment

Score: 4

Explanation: The sentiment is mixed. While the merger itself provides a defined exit for shareholders, the termination of a significant number of stock options for no consideration represents a negative outcome for the option holder, impacting their potential compensation.

Positives

• The merger resulted in Akoya Biosciences shareholders receiving a combination of Quanterix common stock and cash for their shares, providing liquidity and continued equity exposure to the combined entity.

Negatives

• Stock options with an exercise price equal to or greater than the Per Share Merger Consideration were terminated and cancelled for no consideration, resulting in a loss of potential value for the option holder.

Future Outlook

NA

Industry Context

This merger signifies consolidation within the life sciences or diagnostics industry, potentially aiming to leverage synergies, expand market reach, or combine technological capabilities between Akoya Biosciences (likely in spatial biology/proteomics) and Quanterix (likely in ultra-sensitive biomarker detection). Such mergers are common strategies for growth and market leadership in competitive biotech sectors.

Stakeholder Impact

• Shareholders (Akoya Biosciences): Received a combination of Quanterix common stock and cash for their shares, converting their investment into a new entity.
• Employees (Akoya Biosciences, specifically option holders): Those with in-the-money options would have seen them converted or cashed out per the merger terms. However, options with exercise prices at or above the merger consideration were terminated for no value, negatively impacting those specific option holders.

Key Dates

Keywords

Akoya Biosciences, Quanterix Corporation, Merger, SEC Form 4, Insider Trading, Stock Options, Common Stock, Disposition, Corporate Action, Scott Mendel